Meeting
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
Authors
Tim H. Brummendorf
Universitätsklinikum Aachen, Universitätsklinikum Hamburg-Eppendorf, Aachen & Hamburg, Germany
Tim H. Brummendorf , Carlo Gambacorti-Passerini , Philippe Schafhausen , Hanna Jean Khoury , Andreas Hochhaus , Thomas Kindler , Thomas Fischer , Nadine Besson , Eric Leip , Virginia Kelly , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00261846
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6511)
DOI
10.1200/jco.2012.30.15_suppl.6511
Abstract #
6511
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini
Poster
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
First Author: Tony Varughese
Poster
2021 ASCO Annual Meeting
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
First Author: Carlo Gambacorti-Passerini